Loading...
Market
Primary focus of major SRGAP2/SYNGAP1 research grant by end of 2025?
2
Resolution / Starting Odds
Autism • 25%
Cognitive Development • 25%
Neoteny • 25%
Other • 25%
Research grant announcements from government or major research funding bodies
Story
SRGAP2 and SYNGAP1 Genes Linked to Human Brain Development and Autism
Oct 16, 2024, 08:15 AM
New research led by Pierre Vanderhaeghen's team at VIB Life Sciences has uncovered a connection between human-specific genes and the prolonged development of the human brain, known as neoteny. The study links two human-specific genes, SRGAP2 and SYNGAP1, to the control of synapse development speed in human cortical neurons, a process termed 'synaptic neoteny.' This species-specific balancing between SRGAP2 and SYNGAP1 is crucial for proper brain development and may shed light on the evolution of human cognitive abilities. Additionally, the findings provide insights into neurodevelopmental disorders such as autism, suggesting that disruptions in these genes could contribute to autism-like symptoms.
View original story
Similar markets
Genetic research • 25%
Clinical trials • 25%
Data infrastructure • 25%
Other • 25%
Yes • 50%
No • 50%
Successful animal trials • 25%
Initiation of human trials • 25%
Commercial partnership announced • 25%
No significant milestone • 25%
Discovery of a new neuro-target • 25%
Publication in a top-tier journal • 25%
FDA approval for a related treatment • 25%
Other • 25%
National Institutes of Health (NIH) • 25%
World Health Organization (WHO) • 25%
Bill & Melinda Gates Foundation • 25%
Other • 25%
ADHD • 25%
Schizophrenia • 25%
Bipolar Disorder • 25%
Parkinson’s Disease • 25%
Less than $1 million • 33%
$1-5 million • 33%
More than $5 million • 33%
Tumor-removal technologies • 25%
Cancer screening and early detection • 25%
Cancer treatment in underserved communities • 25%
Other • 25%
Gram-positive bacteria • 25%
Gram-negative bacteria • 25%
Fungi • 25%
Other • 25%
Yes • 50%
No • 50%
Lifespan extension • 25%
Immune response • 25%
Body composition changes • 25%
Other • 25%